Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

respiratory burst

39

Histamine H1 receptor

316

Dopamine D2 receptor

311

DNA

282

Serotonin 2a (5-HT2a) receptor

237

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved OTC

38

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

39

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

38

1970

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acute myeloid leukemia

38

Breast cancer

38

Caries

38

Diaper dermatitis

38

Dysgeusia

38

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

39

Primary

38

Secondary

38

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

38

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Smithson, R.

38

Thannhauser, S.J.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

37

Mixture

1

Protein

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

39

CAS

38

PUBCHEM

38

EPA CompTox

36

RXCUI

26

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

3

BLOOD AND BLOOD FORMING ORGANS

1

DERMATOLOGICALS

1

VARIOUS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

MINERAL SUPPLEMENTS

2

ALL OTHER THERAPEUTIC PRODUCTS

1

BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

1

MEDICATED DRESSINGS

1

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER MINERAL SUPPLEMENTS

2

ALL OTHER THERAPEUTIC PRODUCTS

1

I.V. SOLUTION ADDITIVES

1

MEDICATED DRESSINGS

1

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Zinc

2

Detoxifying agents for antineoplastic treatment

1

Electrolyte solutions

1

Various alimentary tract and metabolism products

1

Zinc bandages

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

37

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 39 results

First page disabled
Previous page disabled
1
Next page
Next page

ZINC CATION

13S1S8SF37

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

DIPALMITOYLPHOSPHATIDYLCHOLINE, DL-

2W15RT5V7V

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1970

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

respiratory burst

Conditions:

Respiratory distress syndrome

Dipalmitoylphosphatidylcholine (DPPC) is the main lipid component of surfactant, it reduces surface tension, preventing collapse of the alveoli. It is used in the treatment of neonatal respiratory distress. It is an important constituent of the numbe...

r of surfactant, such as Curosurf®, Lucinactant, Exosurf. Porcine-derived lung surfactant Curosurf® (poractant alfa) intratracheal suspension is indicated for the rescue treatment of respiratory distress syndrome (RDS) in premature infants. Each milliliter of suspension contains 80 mg of poractant alfa that includes 76 mg of phospholipids and 1 mg of protein of which 0.45 mg is SP-B and 0.59 mg is SP-C. The amount of phospholipids is calculated from the content of phosphorus and contains 55 mg of phosphatidylcholine of which 30 mg is dipalmitoylphosphatidylcholine. Curosurf reduces mortality and pneumothoraces associated with RDS. Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use. It contains sinapultide, phospholipids (dipalmitoylphosphatidylcholine, DPPC and palmitoyloleoyl phosphatidylglycerol, POPG) and a fatty acid (palmitic acid). Intended for the prevention of RDS in premature infants at high risk for RDS. FDA approved on March 6, 2012. Exosurf, approved by FDA in 1990, is a protein-free surfactant composed of 85% dipalmitoylphosphatidylcholine, 9% hexadecanol, and 6% tyloxapol by weight.

ZINC DIBUTYRATE

VA6XH8E3JX

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC CITRATE DIHYDRATE

021IBV57IL

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC SUCCINATE

IY01B595GR

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC OROTATE DIHYDRATE

2R18GO895S

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC MONOCARBONATE

K8290PTQ4F

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC NITRIDE

7OOJ6UE14L

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

AMMONIUM PENTACHLOROZINCATE

3ILV18PW3Y

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

AMMONIUM TETRACHLOROZINCATE

NK9T00M5VV

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

respiratory burst

Streptococcus mutans

transformed cell apoptotic process

ultraviolet B-induced damage

T cell mediated immunity

Zinc transporter ZIP1

Zinc transporter ZIP2

Conditions:

Renal insufficiency

Ulcerative colitis

Acute myeloid leukemia

Zinc deficiency

Poison Ivy dermatitis

Diaper dermatitis

Gastrointestinal disorders

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

Showing 1 - 10 of 39 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1